Connect with us

Technology

MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes

Published

on

MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company’s portfolio

NORTHRIDGE, Calif., June 23, 2026 /PRNewswire/ — MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMed™ 780G system integrated with the Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor. The Instinct and Instinct Go sensors, made by Abbott, will be rolled out gradually across Europe starting this month, expanding MiniMed’s sensor portfolio in the region. 

“People with diabetes should not have to choose between flexibility and performance when managing their diabetes — and with MiniMed, they don’t have to,” said Que Dallara, CEO, MiniMed. “Expanding our sensor portfolio across Europe with Instinct and Instinct Go means more people can access the proven outcomes, intelligent insights, and seamless automation MiniMed is known for. This is about meeting people where they are and building technology that fits their life — not the other way around. That’s what drives us every day.”

For people with type 1 diabetes, accurately counting carbs and remembering to take insulin up to 15 minutes before meals can be challenging, often leading to post-meal blood glucose spikes when doses are delayed, missed, or underestimated.

The MiniMed™ 780G system is the only system with Meal Detection™ technology* designed to reduce post-meal blood glucose spikes when users occasionally forget to bolus or underestimate carbs. Paired with the 15-day Instinct sensor—the world’s smallest, thinnest, and most discreet sensor with demonstrated strong glucose accuracy1,2—the MiniMed™ 780G system offers greater choice and flexibility while maintaining proven clinical performance. Recent data from a new randomized crossover study, published in Diabetes Technology & Therapeutics, demonstrated glycemic outcomes were virtually identical when using the MiniMed™ 780G system with either the Simplera Sync™ sensor or Instinct sensor. These results were reinforced by a real-world analysis of over 20,000 U.S. users of the MiniMed 780G system, validating the algorithm’s central role in driving results.6,7

Clinical and real-world evidence suggest that the MiniMed™ 780G system can help people with type 1 diabetes achieve consistent glycemic control that substantially exceeds ADA and international consensus guidelines of 70% Time in Range (TIR), with many users achieving 80% TIR3,4  ∞ when using optimal settings. A separate real-world study of 8,019 U.S. MiniMed™ 780G system users (aged 7 years or older) demonstrated that the system delivered 91% overnight Time in Range5 **^ ∞ which means fewer beeps, fewer alarms and a restful sleep.

For people using multiple daily injections (MDI), diabetes management remains fragmented across disconnected tools, creating constant “mental math” in daily life. The MiniMed Go™ system integrated with the Instinct Go sensor brings it all together in one place. It is the first solution to combine dose tracking with the InPen™ smart insulin pen and real-time CGM data, addressing the therapy adherence gap for MDI users by providing real-time alerts and actionable insights on a single mobile app when doses are missed or blood glucose spikes – helping MDI users stay on top of their diabetes with less effort.

“People with diabetes have different preferences, lifestyles, and needs, which is why choice matters,” said Professor Amir Tirosh of Sheba Medical Center and Tel-Aviv University. “The integration of the Instinct sensor with the MiniMed™ 780G and MiniMed Go™ systems allows more people to access advanced diabetes technology in a way that works for them, while still benefiting from the proven algorithm and clinical outcomes that have made these systems so impactful.”

The Instinct and Instinct Go sensors begin rolling out across European markets this month following CE mark approval earlier this year for integration with the two systems.

Frequently Asked Questions
Q: What is the MiniMed™ 780G system?
A: It’s MiniMed’s most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows and making diabetes management easier and less time-consuming.§

Q: What is the MiniMed Go™ system?
A: The MiniMed Go™ system is a smart diabetes management solution that connects the InPen™ smart insulin pen with either the Simplera™ sensor or Instinct Go sensor, made by Abbott, through the single MiniMed Go™ app. It provides real-time glucose data, dose calculations, missed dose alerts, and actionable guidance, making MDI therapy easier and more connected.

Q: What makes the Instinct sensor different?
A: The Instinct sensor, made by Abbott, is easy to use and comfortable to wear8 for up to 15 days. It’s the world’s smallest1,2, thinnest1 and most discreet2 sensor and is designed to work exclusively with MiniMed smart dosing systems.

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
** Overnight period: 12:00 AM- 6:00 AM [24:00 h–06:00 h]. CareLink™ data including CGM metrics, alarms/alerts, and insulin delivery were evaluated in 8019 US MiniMed™ 780G system users (aged ≥7 years, as of 6 November 2023) who transitioned from the MiniMed™ 770G system and had ≥14 nights of CGM data on both systems. CareLink™ data were analysed between 26 February 2023, and 21 October 2023, for MiniMed™ 770G users, and between 8 August 2023, and 6 November 2023, for MiniMed™ 780G users.
§ Refers to SmartGuard™ feature. Individual results may vary
^ Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
∞ Reached using optimal settings, Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time. SmartGuard™ feature settings for each single patient must be defined by HCPs based on individual targets and specific needs

The sensor shape and appearance, Abbott, and “a” logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image © 2026 Abbott. ™* Third–party brands are trademarks of their respective owners.

Among patient-applied sensors.Data on file. Abbott Diabetes Care, Inc.Thrasher JR, Arrieta A, Niu F, Cameron KR, Cordero TL, Shin J, Rhinehart AS, Vigersky RA. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Diabetes Technol Ther. 2024 Mar;26(S3):24-31. doi: 10.1089/dia.2023.0453. PMID: 38377317Choudhary P, Arrieta A, van den Heuvel T, Castañeda J, Smaniotto V, Cohen O. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. 2024 Mar;26(S3):32-37. doi: 10.1089/dia.2023.0433. PMID: 38377326; PMCID: PMC10890936.McVean, et al. . Diabetes Obes Metab. 2026;28(3):2456-2460Laron-Hirsch, M., et al. Glycemic concordance of Simplera Sync™ and Instinct sensors in MiniMed™ 780G system users: A randomized crossover feasibility study. Diabetes Technology and Therapeutics. DOI:10.1177/15209156261449884Data on file.Alva, Shridhara, Ronald Brazg, Kristin Castorino, Mark Kipnes, David R. Liljenquist, and Hanqing Liu. “Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System.” Diabetes Therapy 14, no. 4 (2023): 767-776. https://doi.org/10.1007/s13300-023-01385-6.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we’ve pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-launches-instinct-sensors-in-europe-giving-people-with-diabetes-more-sensor-choice-with-the-same-proven-outcomes-302806652.html

SOURCE MiniMed

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

JustAI Raises $17M Series A to Build an Agentic Marketing Platform

Published

on

By

New capital from investors Base10 Partners, Y Combinator, and Peak XV Partners, will
help JustAI scale its AI-native platform for enterprise marketing teams in the US

SAN FRANCISCO, June 23, 2026 /PRNewswire/ — JustAI, an AI-native marketing platform helping companies automate personalization, experimentation and decisioning at scale, today announced it has raised $17 million in Series A funding. The round was led by Base10 Partners, with participation from Y Combinator and Peak XV Partners.The round also includes strategic investors and operators from anthropic, Chime and Notion, the CTO of HubSpot, and the founders of Eppo and Vapi.

Marketing and growth teams are under increasing pressure to deliver more output, more personalization and more measurable impact, without scaling headcount or adding more tools. At the same time, the martech landscape has become increasingly fragmented. The 2025 Marketing Technology Landscape counted more than 15,000 martech products, while Gartner’s 2026 CMO Spend Survey found that CMOs are allocating 15.3% of marketing budgets to AI, but only 30% feel ready to scale AI capabilities.

JustAI grew 5X in its annual recurring revenue this year and has ambitious plans to disrupt how marketing is run in large enterprises. It brings together strategy, creative, decisioning and data agents to help marketers move from manual campaign execution to autonomous marketing. Instead of relying on rigid workflows, rules-based segmentation and scattered experimentation history, JustAI gives marketing teams a unified system that can understand user context, generate campaigns, optimize decisions and continuously learn from results.

“We want marketers to spend less time managing tools and more time making the decisions that drive growth,” said Neha Mittal, Founder and CEO of JustAI. “Marketing teams have spent the last decade buying more tools to manage more workflows. But the real opportunity with AI is not another dashboard or another automation layer. It is giving every great marketer the ability to operate with the leverage of an entire team. JustAI is the infrastructure for that shift.”

JustAI’s platform is organized around four coordinated agents:

The Strategy agent helps marketers audit users, segments and product surfaces.The Creative agent turns those insights into brand-forward messaging across channels such as email and in-app experiences.The Decisioning agent optimizes for business goals such as engagement, retention and revenue, while operating within marketer-defined guardrails.The Data agent continuously measures lift, surfaces insights and feeds learnings back into the system.

When describing how JustAI unlocked new capabilities at Coursera, Director of Marketing Vera Hui said: “It would have required a dev team in the past, wouldn’t have done it myself.” JustAI enables companies to predict the next best message or action for each user, replacing manual workflows and deterministic campaign logic with adaptive, AI-powered decisioning. Its infrastructure is designed to execute hundreds of sophisticated campaigns built by agents at scale while giving marketers visibility and control over the system.

JustAI was founded by Neha Mittal and Jeff Hara. Neha brings more than a decade of growth and retention experience from companies including Twitter and Pinterest, where she saw firsthand how difficult it was for marketing teams to personalize at scale using legacy tools. Jeff brings deep experience in machine learning and recommendation systems. Together, the founding team combines expertise across growth, infrastructure, creative and AI.

“JustAI is one of the few teams building a true decisioning and measurement layer for marketing teams that marketers have needed, and the traction backs it up: 5X ARR growth and over $100 million in customer revenue influenced last year. Neha and Jeff combine hard-won growth experience with deep ML depth, and we’re honored they chose us as partners for this round,” noted Rexhi Dollaku, General Partner at Base10 Partners.

The company will use the new funding to expand its engineering and go-to-market teams, deepen its agentic infrastructure, and extend the platform beyond consumer companies into e-commerce and B2B marketing use cases.

To get in touch with the JustAI team, reach out at team@justwords.ai.

About JustAI

JustAI is an AI-native marketing platform that helps companies personalize, experiment and optimize customer engagement at scale. Powered by reinforcement learning and agentic infrastructure, JustAI enables marketing teams to move beyond manual workflows and traditional A/B testing toward AI-first personalization. The company is based in San Francisco and works with high-growth enterprises across consumer, D2C, E-commerce and B2B markets.

About Base10 Partners

Founded by Adeyemi Ajao and TJ Nahigian, Base10 is a San Francisco-based venture capital fund investing in founders who believe purpose is key to profits and in companies that are automating sectors of the Real Economy. Through its program the Advancement Initiative, Base10 donates 50% of profits to underfunded colleges and universities to support financial aid and other key initiatives. Portfolio companies include Notion, Figma, Nubank, Stripe, Popmenu, Aurora Solar, and HappyRobot. Connect via base10.vc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/justai-raises-17m-series-a-to-build-an-agentic-marketing-platform-302807090.html

SOURCE JustAI

Continue Reading

Technology

Valtir and Omnisight Announce Exclusive Strategic Alliance to Advance Proactive Work Zone Safety

Published

on

By

ADDISON, Texas, June 23, 2026 /PRNewswire/ — Valtir, LLC, based in Addison, Texas, and Omnisight, headquartered in Charleston, South Carolina, are proud to announce an exclusive strategic alliance that brings together two leaders with a shared mission: protecting roadway workers through smarter, more proactive technology.

Through this strategic alliance, Valtir will serve as the exclusive North American provider of the Omnisight FusionBLADE® platform for all Trailer and Truck-Mounted Attenuator (TMA) applications, bringing together Valtir’s trusted roadway safety expertise with Omnisight’s advanced AI-powered sensor fusion technology to elevate work zone protection across the industry.

Together, the strategic alliance establishes a new benchmark for TMA-based work zone safety solutions, one that combines physical protection with real-time intelligence.

A Strategic Alliance Built Around Worker Safety

For more than 50 years, Valtir has been a leading provider of roadway safety products, including truck-mounted attenuators, crash cushions, guardrail systems, barriers, and other critical roadside safety hardware. TMAs serve as the last line of defense, absorbing impact and protecting crews when errant vehicles enter a work zone.

Omnisight’s FusionBLADE® technology adds a new layer of protection by helping crews identify potential threats before they reach the attenuator.

Mounted directly onto a TMA, FusionBLADE® continuously monitors approaching traffic using AI-enabled HD video and HD3D radar analytics. The system evaluates vehicle speed, trajectory, lane position, and potential collision risk in real time, providing critical awareness when seconds matter most.

The result is a unified solution that transforms a proven physical safety platform into an intelligent work zone safety system capable of helping crews recognize risk before impact occurs.

“Our exclusive strategic alliance with Omnisight is a defining moment for work zone safety and for Valtir’s role in shaping it. FusionBLADE® transforms any TMA platform from a last line of defense into an active early warning system, giving roadside crews the awareness they need to potentially avoid an impact altogether. Valtir has always been the trusted name in TMA innovation, and as the exclusive North American provider of FusionBLADE® for TMA applications, we are proud to bring this technology to the entire industry, not just our own product line.” — Cecil Brown, Vice President of EAS & Steel Barrier Sales, Valtir.

Intelligence at the Edge, When It Matters Most

FusionBLADE® was designed specifically for the realities of live work zone operations.

The system processes data directly on the vehicle using edge computing technology, eliminating the need for off-site processing and enabling actionable alerts in less than 100 milliseconds.

Because the solution mounts directly onto existing TMA platforms, agencies and contractors can deploy the technology without modifying their attenuators or significantly changing field operations.

FusionBLADE® also automatically records and logs near-miss events, providing safety managers with valuable operational insights and documentation without creating additional workload for field personnel.

What makes the system unique is its ability to combine multiple safety functions into a single platform:

AI-enabled HD video analyticsHD3D radar detection and trackingSpeed monitoringIntrusion and collision-risk detectionAutomated video event captureNear-miss reporting and safety analytics

Rather than relying on separate cameras, DVRs, speed detection systems, and event recording equipment, agencies and contractors can deploy a single integrated solution purpose-built for work zone safety.

“This strategic alliance is about raising the standard for work zone safety,” said Chris McGarty, CEO of Omnisight. “Valtir has built a reputation as a leading provider dedicated to protecting roadway workers and motorists, and we are proud to collaborate with a company that shares our values and commitment to innovation. Together, we’re bringing advanced detection, real-time awareness, and actionable intelligence to work zones, helping transportation agencies move from reactive safety measures to proactive protection.”

From Reactive Protection to Proactive Awareness

Work zone fatalities and serious injuries remain among the transportation industry’s most persistent challenges. Traditional safety measures play an essential role in mitigating consequences when incidents occur, but they often provide little warning before a vehicle enters the work zone.

The Valtir and Omnisight strategic alliance is built around changing that reality. Both companies view this strategic alliance as a natural extension of their commitment to advancing transportation safety through practical, deployable innovation.

About Valtir

Valtir, LLC is a leading provider and global supplier of commercial highway safety products — including truck-mounted attenuators, crash cushions, guardrail, barriers, and more. For over 50 years, Valtir has pioneered the next generation of innovative safety solutions sold to more than 70 countries worldwide. For FusionBLADE® sales inquiries, please visit: https://tinyurl.com/Valtir-FusionBLADE

For Valtir media inquiries, please contact: 
Theresa Stultz
Theresa.Stultz@valtir.com
Valtir.com

About Omnisight

Omnisight develops AI-powered sensor fusion solutions purpose-built for transportation safety. The FusionBLADE® system represents Omnisight’s commitment to advancing worker protection through real-time intelligence, edge processing, and practical deployment in the field.

For Omnisight media inquiries, please contact: 
Julia Skladzinski 
Julia@omnisightusa.com
Omnisightusa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/valtir-and-omnisight-announce-exclusive-strategic-alliance-to-advance-proactive-work-zone-safety-302807719.html

SOURCE Omnisight

Continue Reading

Technology

PulsePoint Expands Omnichannel Intelligence with Ad Server Creative ID Reporting, Giving Marketers NPI-Level Visibility into Rotating Creatives

Published

on

By

NEWARK, N.J., June 23, 2026 /PRNewswire/ — PulsePoint, the leading healthcare marketing technology company, today launched Ad Server Creative ID Reporting, a new capability that connects ad server creative data to individual physician-level insights. This capability gives healthcare marketers something that hasn’t existed before: true granular visibility into the specific rotating creatives that performed best at the NPI level and the intelligence to act on it across their entire omnichannel strategy.

For brands running campaigns through ad servers like Google Campaign Manager 360, creative level data from the ad server has always lived in one place and physician-level data in another. With this new feature, marketers can connect the two, seeing which specific creative message was served to each individual HCP, even when multiple creatives are rotating within the same ad server placement. Combined with PulsePoint’s existing channel-level behavioral data, marketers can now optimize by both channel and creative simultaneously to understand not just where an HCP engages, but what message moves them on each channel.

Butler/Till, a leading healthcare marketing agency, and Salix Pharmaceuticals were early development partners in bringing Ad Server Creative ID Reporting to life. Both organizations were uniquely positioned to pilot the capability, running the kind of sophisticated, multi-creative, omnichannel HCP campaigns where creative-level NPI attribution makes a big difference. 

“Traditional campaign constructs did not allow us to deploy message journeys. Now we are able to both align our segment messaging and consider next best action at the provider level,” said Christine Tucco, Director of Digital Strategy at Salix Pharmaceuticals “We saw an opportunity to solve a clear gap in executing true omnichannel personalization, so we partnered early to help shape the solution. I would tell others that if they are serious about providing the right message in the right channel, leaning in early to innovations like this is critical.”

“Getting visibility into which creative messages HCPs were being served was essential to fueling our client’s omnichannel strategy, but achieving it the way we knew how would have disrupted our trafficking processes and conflicted with ad-serving best practices. When we shared that challenge with PulsePoint, they didn’t just listen. They solved it,” said Danielle Fox, Senior Integrated Planning Director at Butler/Till. “After iterating together to get it right, the resulting solution was easy to implement, saved us from quadrupling our trafficking needs, and gave us the content intelligence our client’s strategy demanded.”  

Ad Server Creative ID Reporting automatically stitches ad server creative IDs directly to NPI-level data within PulsePoint’s platform. The result is physician-level creative attribution that marketing teams can act on, understanding not just who was reached, but which message reached them, how they engaged, and what that means for how the brand communicates with that HCP going forward for true personalization and omnichannel success.

“Our clients are running campaigns of real sophistication with multiple creatives, multiple segments, multiple channels, and multiple platforms. Ad Server Creative ID Reporting is about interoperability and bringing the signals that live in ad servers like CM360 into PulsePoint’s physician-level data environment,” said Ezra Suveyke, Chief Product and Technology Officer at PulsePoint. “Marketers get the creative-level NPI attribution to match the complexity of how they’re actually running omnichannel campaigns and they get it without the manual lift that used to make that kind of insight cumbersome.”

Because Ad Server Creative ID data flows directly into PulsePoint’s Report Builder alongside existing campaign data, there are no new workflows to build. Teams can add the Ad Server Creative ID dimension to any existing report template and schedule delivery automatically. 

About PulsePoint

PulsePoint, a division of Internet Brands, is a leading advertising technology company dedicated to moving health marketing forward. We enable healthcare marketers to engage HCP and DTC audiences across all digital channels and best-fit environments. Powered by proprietary first-party data and methodology, PulsePoint’s platform drives measurable results for our clients, leading to better healthcare outcomes for all. For more information, visit pulsepoint.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsepoint-expands-omnichannel-intelligence-with-ad-server-creative-id-reporting-giving-marketers-npi-level-visibility-into-rotating-creatives-302808070.html

SOURCE PulsePoint

Continue Reading

Trending